Literature DB >> 33157318

Clinical Utility of Change in Nonalcoholic Fatty Liver Disease Activity Score and Change in Fibrosis in NAFLD.

Nobuharu Tamaki1, Nagambika Munaganuru2, Jinho Jung2, Aed Qas Yonan2, Richele Bettencourt2, Veeral Ajmera2, Mark A Valasek3, Cynthia Behling4, Rohit Loomba5.   

Abstract

The Nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS) has been applied as a method for evaluating treatment response, and a ≥2-point improvement in NAS has been commonly used as an accepted end point in phase 2b clinical trials in nonalcoholic steatohepatitis.1,2 Although liver fibrosis is the strongest histologic predictor of liver-related outcome and all-cause mortality in NAFLD,3,4 the association between change in NAS and change in fibrosis stage has not been fully verified. Therefore, we aimed to examine the association between change in NAS and change in fibrosis stage in well-characterized patients with NAFLD who had a paired liver biopsy assessment.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2020        PMID： 33157318      PMCID： PMC8438785          DOI： 10.1016/j.cgh.2020.11.005

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


  7 in total

1.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Authors:  Brent A Neuschwander-Tetri; Rohit Loomba; Arun J Sanyal; Joel E Lavine; Mark L Van Natta; Manal F Abdelmalek; Naga Chalasani; Srinivasan Dasarathy; Anna Mae Diehl; Bilal Hameed; Kris V Kowdley; Arthur McCullough; Norah Terrault; Jeanne M Clark; James Tonascia; Elizabeth M Brunt; David E Kleiner; Edward Doo
Journal:  Lancet       Date:  2014-11-07       Impact factor: 79.321

2.  Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

Authors:  Rod S Taylor; Rebecca J Taylor; Sue Bayliss; Hannes Hagström; Patrik Nasr; Jorn M Schattenberg; Masatoshi Ishigami; Hidenori Toyoda; Vincent Wai-Sun Wong; Noam Peleg; Amir Shlomai; Giada Sebastiani; Yuya Seko; Neeraj Bhala; Zobair M Younossi; Quentin M Anstee; Stuart McPherson; Philip N Newsome
Journal:  Gastroenterology       Date:  2020-02-04       Impact factor: 22.682

Review 3.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.

Authors:  Parambir S Dulai; Siddharth Singh; Janki Patel; Meera Soni; Larry J Prokop; Zobair Younossi; Giada Sebastiani; Mattias Ekstedt; Hannes Hagstrom; Patrik Nasr; Per Stal; Vincent Wai-Sun Wong; Stergios Kechagias; Rolf Hultcrantz; Rohit Loomba
Journal:  Hepatology       Date:  2017-03-31       Impact factor: 17.425

Review 4.  Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum.

Authors:  Amanda Cheung; Brent A Neuschwander-Tetri; David E Kleiner; Elmer Schabel; Mary Rinella; Stephen Harrison; Vlad Ratziu; Arun J Sanyal; Rohit Loomba; Sophie Jeannin Megnien; Richard Torstenson; Veronica Miller
Journal:  Hepatology       Date:  2019-11       Impact factor: 17.425

5.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

6.  Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH.

Authors:  Rohit Loomba; Brent A Neuschwander-Tetri; Arun Sanyal; Naga Chalasani; Anna Mae Diehl; Norah Terrault; Kris Kowdley; Srinivasan Dasarathy; David Kleiner; Cynthia Behling; Joel Lavine; Mark Van Natta; Michael Middleton; James Tonascia; Claude Sirlin
Journal:  Hepatology       Date:  2020-10-09       Impact factor: 17.425

7.  Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Laura A Wilson; Cynthia Behling; Cynthia Guy; Melissa Contos; Oscar Cummings; Matthew Yeh; Ryan Gill; Naga Chalasani; Brent A Neuschwander-Tetri; Anna Mae Diehl; Srinivasan Dasarathy; Norah Terrault; Kris Kowdley; Rohit Loomba; Patricia Belt; James Tonascia; Joel E Lavine; Arun J Sanyal
Journal:  JAMA Netw Open       Date:  2019-10-02
  7 in total
  3 in total

Review 1.  Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD.

Authors:  Nobuharu Tamaki; Veeral Ajmera; Rohit Loomba
Journal:  Nat Rev Endocrinol       Date:  2021-11-23       Impact factor: 47.564

2.  Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease.

Authors:  Nobuharu Tamaki; Nagambika Munaganuru; Jinho Jung; Aed Qas Yonan; Rohan R Loomba; Richele Bettencourt; Veeral Ajmera; Mark A Valasek; Cynthia Behling; Claude B Sirlin; Rohit Loomba
Journal:  Gut       Date:  2021-04-21       Impact factor: 23.059

3.  Improvement in insulin sensitivity and prevention of high fat diet-induced liver pathology using a CXCR2 antagonist.

Authors:  Brett E Phillips; Louise Lantier; Carl Engman; Yesica Garciafigueroa; Aatur Singhi; Massimo Trucco; Christos Mantzoros; David Wasserman; Nick Giannoukakis
Journal:  Cardiovasc Diabetol       Date:  2022-07-12       Impact factor: 8.949
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.